Headlands Research's Summit Portland Celebrates 50 Years in Alzheimer's Research

Headlands Research's Summit Portland facility in Portland, Oregon, is celebrating 50 years of operations in clinical research. The site has participated in trials contributing to every FDA-approved class of Alzheimer's medication since 1993.

Over its five-decade history, Summit Portland has amassed considerable experience and expertise in conducting clinical trials for central nervous system (CNS) disorders, particularly Alzheimer's disease. This sustained involvement has positioned the facility as a key contributor to the advancement of new therapeutic options and the improvement of patient outcomes.

The research site's contributions extend to other neurological conditions as well. The company aims to continuously expand its research areas and refine its methodologies, seeking effective treatments for diseases that currently lack curative solutions.

Summit Portland's achievements highlight the significance of long-term research collaboration in driving medical progress. The organization continues its investment in clinical research, aiming to further solidify its role in advancing treatments for neurological conditions.